换一批Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
第一作者：
Sabine B,Zollner
第一单位：
Preclinical Research and Development, CSL Behring GmbH, 35041 Marburg, Germany. Electronic address: Sabine.Zollner@cslbehring.com.
作者：
关键词
ADAAUCAUC from 0 to 24hoursAUC from 0 to last timepointAUC(0-last)AUC(0–24h)B-domain deletedBDDC(max)CFTCHOCICTChinese hamster ovaryELISAETPFVIIIGLPPTFTGAVWFaPCCaPTTactivated partial thromboplastin timeactivated prothrombin complex concentrateactivated recombinant factor VIIIanti-drug antibodyarea under the curveclot formation timeclotting timeconfidence intervalendogenous thrombin potentialenzyme-linked immunosorbent assayfactor VIIIgood laboratory practicehalf-lifehemostasismaximum concentrationpotentiation of thrombus formationpreclinicalrFVIIIrFVIIIarVIII-SingleChainrecombinantrecombinant factor VIIIt(1/2)t(max)thrombin generation assaytime taken to achieve C(max)von Willebrand factor
医学主题词
动物(Animals);血液凝固因子(Blood Coagulation Factors);因子Ⅷ(Factor VIII);女(雌)性(Female);血友病A(Hemophilia A);止血(Hemostasis);人类(Humans);男(雄)性(Male);小鼠(Mice);小鼠, 基因敲除(Mice, Knockout);兔(Rabbits);随机分配(Random Allocation);重组蛋白质类(Recombinant Proteins)
DOI
10.1016/j.thromres.2013.06.017
PMID
23830969
发布时间
2016-11-25
- 浏览124
Thrombosis research
280-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
